Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PD-1 Knockout Could Be Caribou’s Key To Allo CAR-T Success

Early Response Rate Exceeds Competitors

Executive Summary

While it is still early days for Caribou, early signs suggest it could have the first off-the-shelf program to rival established CAR-T therapies.

You may also be interested in...



Caribou Hit By Familiar Allo CAR-T Durability Problems

Like some of its allo CAR-T rivals, CB-010’s early promise has fallen away, but Caribou still hopes a higher dose can bring with it real durability of response.

Bayer Shuffles Atara’s CAR-Ts Out Of Its Cell Therapy Deck

Bayer is handing back rights to two early-stage off-the-shelf CAR-Ts to Atara, but the split could still be good news for the biotech company.

Gamida Set For Breakthrough Transplant Therapy Approval – But Cash Problems Could Hit Launch

With a new CEO at the helm, Gamida is closing in on an FDA approval, but a lack of cash could hobble its US launch efforts for allogeneic cell therapy product omidubicel.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146378

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel